Cambio de Dirección
5 de febrero de 2024
Scancell Holdings plc
("Scancell" o la "Compañía")
Directorate Change and Appointment of Head of Development
· Dr Sally Adams to retire as an Executive Director of the Board and as Chief Development Officer
· Dr Callum Scott has been appointed as Head of Development
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that Dr Sally Adams is retiring as an Executive Director of the Board and as Chief Development Officer. Dr Callum Scott tiene been appointed as the new Head of Development, effective immediately, and Sally will remain with the Company part time for 6 months to ensure a smooth and effective transition of responsibilities.
Dr Scott brings over 15 years of experience in vaccine research and development. Previously, he held the role of Technical Transfer & Formulation Development Manager at UK biotech firm Allergy Therapeutics (AIM: AGY) where he led all CMC (Chemistry, Manufacturing and Controls)/product development activities relating to their VLP Peanut project through Phases 1-3 including IND approvals. Dr Scott holds a PhD in Molecular Microbiology and a BSc in Biochemistry, both from Heriot-Watt University.
Profesora Lindy Durrant, directora ejecutiva de Scancell, comentado: "Firstly, on behalf of the Scancell Board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the Board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future.
"I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."
Dr Sally Adams, Chief Development Officer, said: "It has been a privilege to work with Lindy and the Scancell team for the last 15 years, helping to develop successful manufacturing processes and quality systems and to take three products into the clinic. The recent clinical successes with SCIB1 and Modi-1 have been the culmination of a huge team effort across the Company, and I have every confidence that these results will be built upon in the future. I wish Lindy and the Company every success."
Dr Callum Scott, Head of Development, commented: "Joining Scancell when SCIB1 and Modi-1 cancer vaccines are making highly promising clinical progress is very exciting, with further data from the SCOPE study expected in mid-2024 and ModiFY trial later this year. I look forward to contributing to the rapid advancement of these innovative and high-value assets through the clinic and towards commercialisation and working with Lindy and the Scancell team."
Para más información, por favor póngase en contacto con: | |
Scancell Holdings plc | +44 0 20 3709 5700 |
Dr. Jean-Michel Cosséry, presidente no ejecutivo | |
Profesora Lindy Durrant, directora ejecutiva | |
Stifel Nicolaus Europa limitada (Asesor designado y conjunto Broker) | +44 0 20 7710 7600 |
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Banca de Inversión en Salud) | |
Nick Adams/Nick Harland (corretaje corporativo)
| |
WG Partners LLP (Conjunto Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby
| +44 0 20 3705 9330
|
Panmure Gordon (Reino Unido) Limited (Articulación Broker) | +44 0 20 7886 2500 |
Freddy Crossley / Emma Earl (Finanzas corporativas) | |
Rupert Dearden (Corretaje corporativo) | |
Consejo ICR | +44 0 20 3709 5700 |
Mary-Jane Elliott/Matthew Neal/Chris Welsh |
|
Sobre Scancell
Scancell es una compañía biofarmacéutica en etapa clínica que está aprovechando su investigación patentada, desarrollada durante muchos años de estudio del sistema inmunitario adaptativo humano, para generar medicamentos novedosos para tratar necesidades importantes no satisfechas en cáncer y enfermedades infecciosas. La Compañía está construyendo una cartera de productos innovadores utilizando sus cuatro plataformas tecnológicas: Moditope® e ImmunoBody® para vacunas y GlyMab® y AvidiMab® para anticuerpos.
Las respuestas inmunitarias adaptativas incluyen anticuerpos y células T (CD4 y CD8), que pueden reconocer células dañadas o infectadas. Para destruir dichas células cancerosas o infectadas, Scancell utiliza vacunas para inducir respuestas inmunitarias o anticuerpos monoclonales (mAb) para redirigir las células inmunitarias o los fármacos. El enfoque único de la Compañía es que sus productos innovadores apuntan a modificaciones de proteínas y lípidos. Para las vacunas (Moditope® e ImmunoBody®) esto incluye la citrulinación y la homocitrulación de proteínas, mientras que su cartera de mAb se dirige a los glicanos o azúcares que se agregan a las proteínas y/o lípidos (GlyMab®) o mejora la potencia de los anticuerpos y su capacidad para destruir directamente las células tumorales (AvidiMab®).
Para obtener más información sobre Scancell, visite: https://www.scancell.co.uk/
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.